Feb 25, 2021
Thursday 25 February, 2021
COVID LEVEL 1: In Person: SBS Reception Lounge, at the IIB and SBS entrance to the Thomas Building, 3a Symonds St.
COVID LEVEL 2/3: Webinar: Login details to come
Please RSVP to email@example.com
This month we welcome guest speaker Dr Peter Surman "New Therapeutic Uses for Existing Drugs”, Chief Scientific Officer, Douglas Pharmaceuticals..
We are delighted to invite you on behalf of the IIB to the first forum in our series of networking events for 2021 to be held on Thursday 25 February 2021 from 4.30 for a 5.00 pm start (COVID LEVEL 1). OR 5pm ONLINE start (COVID LEVEL 2/3).
Eighty percent of drugs that enter human clinical testing are never approved for use. This means that for every five drugs that make it into the clinic, there are four that failed to show effectiveness for treating the disease or condition the drug was designed to treat. This high failure rate means there are many existing, partially developed therapeutic candidates with known pharmacology, formulation, and potential toxicity.
However, there is new opportunities for existing drugs or biologics that have been approved by FDA, for novel indications "repositioning" which builds upon previous research and development efforts, so new candidate therapies can be advanced to clinical trials for a new use more quickly than starting from scratch.
Dr Peter Surman, Chief Scientific Officer, will discuss Douglas Pharmaceuticals drug repurposing program.
Douglas Pharmaceuticals is a New Zealand success story – a rapidly expanding pharmaceutical company with a reputation for high manufacturing standards, quality products and outstanding client service.
The University is well serviced by bus routes, and car parking is available under the University of Auckland Business School (the Owen G Glenn Building) on Grafton Rd.